Study uncovers how prostate cancer becomes deadly, offers hope for new treatments
FOXA2 and NKX2-1 drive the transformation of prostate cancer into lethal neuroendocrine prostate cancer (NEPC), and inhibition of the CBP/p300 epigenetic regulators by drugs such as CCS1477 can halt this process in preclinical models
The study maps a step-by-step process in which FOXA2 and NKX2-1 proteins reprogram prostate cancer cells into aggressive neuroendocrine prostate cancer (NEPC). It identifies CBP and p300 as essential epigenetic drivers of this transition and demonstrates that their inhibition by the drug CCS1477 effectively suppresses NEPC growth in laboratory and animal models, suggesting a promising therapeutic strategy.
Understanding the molecular drivers that cause prostate cancer to become resistant and more lethal provides a target for new treatments. By revealing that FOXA2/NKX2-1 reprogramming and CBP/p300 activity underlie the emergence of neuroendocrine prostate cancer, this work identifies potential intervention points that could improve outcomes for patients with an otherwise untreatable disease.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience